目录号 | 产品详情 | 靶点 | |
---|---|---|---|
TMIH-0315 | |||
Lurasidone Inactive Metabolite 14283-d8 是 Lurasidone Inactive Metabolite 14283 的氘代化合物。Lurasidone Inactive Metabolite 14283 的 CAS 号为 186204-31-9。 | |||
TMIH-0198 | |||
DM-3411-d8 是 DM-3411 的氘代化合物。DM-3411 的 CAS 号为 913611-97-9。Brexpiprazole是人5-HT1A和多巴胺受体的部分激动剂,Ki分别为0.12 和 0.3 nM。它也是5-HT2A受体的拮抗剂,Ki为 0.47 nM,可作为非典型抗精神病药。 | |||
T19667 | |||
R-138727 is a novel P2Y12 receptor inhibitor. | |||
T32000 | |||
GSK-1071306 is a bio-active chemical. | |||
T32828 | |||
LNC-119 is an aminosteroid. | |||
T30302 | |||
BAY-751098 is a bio-active chemical. | |||
T30191 | |||
Atecegatran 常被当作一种抗凝血剂属于,可用来治疗心血管疾病。 | |||
T11987 | Others | ||
Mebeverine alcohol is a metabolite of Mebeverine. | |||
T32003 | |||
GSK-1268997 is a bio-active chemical. | |||
TMIH-0023 | |||
1-[3-carboxypropyl]-3,7-dimethylxanthine-d6 是 1-[3-carboxypropyl]-3,7-dimethylxanthine 的氘代化合物。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-00844 | HSD11B2 Protein, Human, Recombinant (His) | Human | P. pastoris (Yeast) | ||
Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids. HSD11B2 Protein, Human, Recombinant (His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 46.1 kDa and the accession number is P80365.
|
|||||
TMPY-03414 | ABHD10 Protein, Human, Recombinant (aa 53-306, His) | Human | Baculovirus Insect Cells | ||
Mycophenolic acid (MPA), the active metabolite of the immunosuppressant mycophenolate mofetil (MMF), is primarily metabolized by glucuronidation to a phenolic glucuronide (MPAG) and an acyl glucuronide (AcMPAG). It is known that AcMPAG, which may be an immunotoxic metabolite, is deglucuronidated in human liver. AcMPAG deglucuronidation activity was detected in both human liver cytosol (HLC) and microsomes (HLM). By purification from HLC with column chromatographic purification steps, the enzyme responsible for AcMPAG deglucuronidationis identified as α/β hydrolase domain containing 1 (ABHD1). Recombinant ABHD1 expressed in Sf9 cells efficiently deglucuronidated AcMPAG with a K(m) value of 1.7 ± 1.2 μM, which was similar to those in HLM, HLC, and human liver homogenates (HLH). Immunoblot analysis revealed ABHD1 protein expression in both HLC and HLM. The AcMPAG deglucuronidation by recombinant ABHD1, HLC, and HLH were potently inhibited by AgNO(3), CdCl(2), CuCl(2), PMSF, bis-p-nitrophenylphosphate, and DTNB. The CL(int) value of AcMPAG formation from MPA, which was catalyzed by human UGT2B7, in HLH was increased by 1.8-fold in the presence of PMSF. Thus, human ABHD1 would affect the formation of AcMPAG, the immunotoxic metabolite.
|
|||||
TMPH-00843 | HSD11B1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7-ketocholesterol to 7-beta-hydroxycholesterol. HSD11B1 Protein, Human, Recombinant (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 45.5 kDa and the accession number is P28845.
|
|||||
TMPY-00320 | APOA1BP Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
APOA1BP, now renamed NAXE, encodes an epimerase essential in the cellular metabolite repair for NADHX and NADPHX. The enzyme catalyzes the epimerization of NAD(P)HX, thereby avoiding the accumulation of toxic metabolites.Pathogenic biallelic mutations in NAXE in children from four families with (sub-) acute-onset ataxia, cerebellar edema, spinal myelopathy, and skin lesions.
|
|||||
TMPH-02615 | CBS Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine. Also involved in the production of hydrogen sulfide, a gasotransmitter with signaling and cytoprotective effects on neurons.
|
|||||
TMPH-01597 | KYAT1 Protein, Human, Recombinant (His & SUMO) | Human | E. coli | ||
Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA), an intermediate in the tryptophan catabolic pathway which is also a broad spectrum antagonist of the three ionotropic excitatory amino acid receptors among others. Also metabolizes the cysteine conjugates of certain halogenated alkenes and alkanes to form reactive metabolites. Catalyzes the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond.
|
|||||
TMPY-02420 | HEMK2 Protein, Human, Recombinant (His) | Human | E. coli | ||
N6AMT1 (N-6 Adenine-Specific DNA Methyltransferase 1) is a Protein Coding gene. 2 alternatively spliced human isoforms have been reported. This gene encodes an N(6)-adenine-specific DNA methyltransferase. It belongs to the eukaryotic/archaeal PrmC-related family. The encoded enzyme may be involved in the methylation of release factor I during translation termination. N6AMT1 has a significant role in determining susceptibility to arsenic toxicity and carcinogenicity because of its specific activity in methylating MMAIII to DMA and other unknown mechanisms. N6AMT1 methylates the toxic inorganic arsenic (iAs) metabolite, monomethylarsonous acid (MMA), to the less toxic dimethylarsinic acid (DMA). N6AMT1 polymorphisms were associated with arsenic methylation in Andean women, independent of AS3MT.
|